ArticleFrontiers in pain research (Lausanne, Switzerland)2025
Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024).
Article in Frontiers in pain research (Lausanne, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Headache is a common adverse drug reaction (ADR) across diverse therapeutic classes, yet systematic evaluations of drug-associated headaches in real-world settings are limited. This study aimed to explore the association between various medications and the reporting of headache as an ADR using the FDA-Adverse Event Reporting System (FAERS). Methods: We conducted a retrospective disproportionality analysis using FAERS data from Q1-2018 to Q4-2024. Duplicate reports were removed per FDA guidelines. Reports with headache as an adverse event and drugs classified as Primary Suspect were included. Disproportionality metrics - Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)-were calculated to identify signals. Drugs were classified according to the Anatomical Therapeutic Chemical(ATC) classification system, and time-to-onset analyses were performed. Results: A total of 313,166 headache-associated cases were identified. Females (66.66%) and patients aged 51-65 years (21.35%) were most commonly affected. The drugs with the highest headache risk based on ROR included glecaprevir/pibrentasvir (ROR = 10.445), sofosbuvir/velpatasvir (ROR = 9.729), and eptinezumab-jjmr (ROR = 6.775). Top frequently reported drugs were apremilast, treprostinil, and adalimumab. Calcium homeostasis agents (ROR = 6.268) and systemic antivirals (ROR = 4.259) emerged as the ATC classes with the highest headache signal strength. Early-onset headaches (≤7days) were particularly associated with ofatumumab and fingolimod. Late-onset headaches (>90days) were linked to treprostinil and infliximab-dyyb. Conclusion: This large-scale pharmacovigilance study identifies multiple drugs and therapeutic classes with significant associations to headache as an ADR. These findings highlight the need for proactive headache monitoring, particularly during early treatment phases, and warrant further prospective investigations to understand mechanisms and preventive strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.